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Randomized, controlled trials (RCTs) have convincingly
proven that in patients with advanced (New York Heart
Association functional class III/IV) systolic (left ventricular
[LV] ejection fraction 35%) heart failure and wide QRS
complex (QRS 120 ms), cardiac resynchronization ther-
apy (CRT) improves functional status and quality of life (1),
decreases heart failure hospitalizations (2), and prolongs
survival (3). However, the lack of response to CRT in a
substantial portion of patients (one-third) has been a con-
sistent finding (4).
See page 1509
The lack of a uniform response to an intervention is not
unique to trials involving devices. RCTs are interpreted
based on the mean response of all participants in the
treatment arm to the intervention. A positive trial simply
indicates that the mean change observed in the treatment
group is in the desired direction but provides no clue to
individual responses to the intervention. It is likely that
some participants would experience a greater benefit (super
responders) than others (responders), yet some may not
benefit at all (nonresponders) and few may even experience
harmful effects.
The inability to predict individual responses has been the
Achilles’ heel of heart failure RCTs, including CRT trials.
It is remarkable, however, that for CRT, many more efforts
have been devoted to identifying and predicting responders
(5). Initial small single-center studies reported a favorable
outlook for several echocardiographic measures of mechan-
ical dyssynchrony in predicting responders (6–8). A subse-
quent large multicenter study, however, the PROSPECT
(Predictors of Response to CRT) trial, failed to identify a
useful measurement using conventional and tissue Doppler–
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of this paper to disclose.based methods (9). A retrospective subanalysis of that study
suggested that assessment of factors such as sex, etiology,
and severity of heart failure may enhance the likelihood of
identifying responders (10). Likewise, total scar burden has
also been proposed to help in predicting responders (11).
Recently, a meta-analysis of 5 RCTs evaluating CRT in
heart failure found this modality to be effective in reducing
mortality and hospitalization only in patients with a QRS
complex 150 ms (12). This important study not only
identified an important parameter for selecting responders, but
it also provided indirect support for efforts aimed at identifying
predictors of CRT response in individual patients.
Cumulative clinical experiences have indeed identified
several parameters that could potentially predict individuals
more likely to respond to CRT, including LV dyssynchrony,
as assessed by strain imaging (13), optimal LV lead position
(14), and absence of myocardial scar (15). A recent analysis
of 397 patients with ischemic heart failure who received
CRT showed that these 3 parameters were not only inde-
pendent predictors of 3-year survival, but their addition
provided incremental prognostic value (16). Thus, the stage
had been set for a prospective, randomized study to assess
the impact of a targeted strategy based on these parameters
compared with usual care.
In this issue of the Journal, Khan et al. (17) report the
results of a study integrating information collected by strain
imaging that identified the most delayed segment of con-
traction and absence of scar. The authors conducted an
RCT to assess the impact of targeting LV lead placement at
the most delayed viable segment defined by speckle-tracking
echocardiography compared with usual care. A total of 247
consecutive patients with New York Heart Association
functional class III/IV, LV ejection fraction 35%, and
intraventricular conduction delay (QRS complex 120 ms)
were evaluated at 2 centers between April 2009 and July
2010.
The primary endpoint was 15% reduction in LV
end-systolic volume at 6 months. Secondary endpoints
included 1 improvement in New York Heart Association
functional class, all-cause mortality, and combined all-cause
mortality and heart failure–related hospitalization.
The image quality was not suitable for 2-dimensional
radial strain analysis in 27 patients (11%), who were
excluded; thus, a total of 220 patients were randomized.
In the intervention group, an attempt was made to
position the LV lead at the optimal site as defined by
2-dimensional speckle-tracking radial strain imaging. A
value of10% was used to define scar. In the control group,
patients underwent standard CRT without echocardio-
graphic guidance. Blinding was maintained throughout the
study, with all assessors of the primary and secondary
endpoints remaining blinded to group assignment. Com-
pared with usual care, the intervention group had a greater
proportion of responders at 6 months (70% vs. 50%, p 
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0.003), and a lower rate of heart failure–related hospitalization.
Khan et al. (17) should be commended for the successful
completion of this RCT, which provokes several thoughts.
1. The difficulty of designing the “perfect trial.” When
CRT was initially introduced, its benefits had to be
proven first, but if we knew then what we know now, we
would have selected a QRS complex 150 ms as a
selection criterion and would have avoided a scarred area
as a lead placement site.
Thus, this trial could serve as a reminder that although
when designing clinical trials we need to be as visionary
as possible and include as many mechanistic studies as
feasible, the reality nevertheless is that there is no
alternative to the process of continuing learning from the
accumulated clinical experience gained from applying the
new intervention and build on this information to refine
the original intervention. Stages cannot be burned. Fine-
tuning an intervention requires time to incorporate newly
acquired information into hypotheses that require testing.
2. The “second wave” of an RCT should be designed to
assess the effect of the intervention on surrogate end-
points. It is unrealistic to look for a decrease in mortality
in such trials. The approach that Kahn et al. chose is
sound and logical. The mid term effect on LV systolic
volume represents a solid surrogate endpoint. It is
reassuring that the effect on heart failure hospitalization
was in the right direction in this trial; however, it is
important to keep in mind that the impact of an
intervention on hospitalization and death cannot be
assessed by such a small number of events (18 deaths and
18 hospitalizations among patients who received CRT).
It is certainly appropriate and desirable to track these
events; however, the rapid accumulation of new knowl-
edge is breathtaking, and there will undoubtedly be
newer imaging modalities as well as technical innova-
tions in the search for identifying responders. The only
practical way to assess their role is by examining surro-
gate endpoints.
3. An important limitation that the authors identified is the
failure to use this approach in one-third of the patients
being considered for CRT. Therefore, this trial is likely
to not only stimulate further innovations in imaging
modalities and technical approaches, but also more
clinical trials that incorporate the assessment of the role
of surgical approaches in their design.
Although the findings of this trial may not mandate
the selection of the most delayed viable segment when
CRT is being considered, they do call into question the
wisdom of not selecting the most likely responders when
an invasive and costly procedure such as CRT is initiated.
Identifying responders to new interventions and strategies
is a major challenge that future heart failure trials need to
meet.Reprint requests and correspondence: Dr. Jalal K. Ghali, DMC
Cardiovascular Institute, 3990 John R, Suite 3970, Detroit, Mich-
igan 48201. E-mail: jghali@dmc.org.
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